315 related articles for article (PubMed ID: 22366248)
1. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
2. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
[TBL] [Abstract][Full Text] [Related]
4. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
5. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Chattopadhyay M; Kodela R; Nath N; Dastagirzada YM; Velázquez-Martínez CA; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):715-22. PubMed ID: 22222427
[TBL] [Abstract][Full Text] [Related]
6. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
[TBL] [Abstract][Full Text] [Related]
7. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
Kashfi K
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
[TBL] [Abstract][Full Text] [Related]
8. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
Vannini F; Kodela R; Chattopadhyay M; Kashfi K
Redox Biol; 2015 Aug; 5():421. PubMed ID: 28162291
[TBL] [Abstract][Full Text] [Related]
9. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders.
Lee M; McGeer E; Kodela R; Kashfi K; McGeer PL
Glia; 2013 Oct; 61(10):1724-34. PubMed ID: 23918470
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
Williams JL; Borgo S; Hasan I; Castillo E; Traganos F; Rigas B
Cancer Res; 2001 Apr; 61(8):3285-9. PubMed ID: 11309281
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
12. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
Kashfi K; Borgo S; Williams JL; Chen J; Gao J; Glekas A; Benedini F; Del Soldato P; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):978-88. PubMed ID: 15528453
[TBL] [Abstract][Full Text] [Related]
13. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
Kashfi K; Chattopadhyay M; Kodela R
Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention.
Williams JL; Nath N; Chen J; Hundley TR; Gao J; Kopelovich L; Kashfi K; Rigas B
Cancer Res; 2003 Nov; 63(22):7613-8. PubMed ID: 14633677
[TBL] [Abstract][Full Text] [Related]
15. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
16. NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation.
Chattopadhyay M; Goswami S; Rodes DB; Kodela R; Velazquez CA; Boring D; Crowell JA; Kashfi K
Cancer Lett; 2010 Dec; 298(2):204-11. PubMed ID: 20674154
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines.
Pawlik M; Pajdo R; Kwiecien S; Ptak-Belowska A; Sliwowski Z; Mazurkiewicz-Janik M; Konturek SJ; Pawlik WW; Brzozowski T
J Physiol Pharmacol; 2011 Feb; 62(1):75-86. PubMed ID: 21451212
[TBL] [Abstract][Full Text] [Related]
18. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
19. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
Yeh RK; Chen J; Williams JL; Baluch M; Hundley TR; Rosenbaum RE; Kalala S; Traganos F; Benardini F; del Soldato P; Kashfi K; Rigas B
Biochem Pharmacol; 2004 Jun; 67(12):2197-205. PubMed ID: 15163551
[TBL] [Abstract][Full Text] [Related]
20. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
